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Intraoperative redosing of prophylactic antibiotics is recommended for pro-
longed surgical procedures, although its efficacy has not been assessed.
We retrospectively compared the risk of surgical site infections in 1,548
patients who underwent cardiac surgery lasting >240 min after preoperative
administration of cefazolin prophylaxis. The overall risk of surgical site infec-
tion was similar among patients with (43 [9.4%] of 459) and without (101
[9.3%] of 1,089) intraoperative redosing (odds ratio [OR] 1.01, 95% confi-
dence interval [CI] 0.70-1.47). However, redosing was beneficial in proce-
dures lasting >400 min: infection occurred in 14 (7.7%) of 182 patients with
redosing and in 32 (16.0%) of 200 patients without (adjusted OR 0.44, 95%
CI 0.23-0.86). Intraoperative redosing of cefazolin was associated with a
16% reduction in the overall risk for surgical site infection after cardiac sur-
gery, including procedures lasting <240 min.
Surgical site infections are important causes of illness
and resource utilization (1,2). Perioperative antibiotic pro-
phylaxis is widely used to reduce their incidence. On the
basis of pharmacokinetic considerations, most published
guidelines recommend intraoperative redosing of the pro-
phylactic antibiotic for procedures of prolonged duration to
maintain effective antibiotic concentrations (1,3-6).
Support for intraoperative redosing of antibiotics has
been inferred from observational studies in which increased
duration of surgery was associated with increased risk for
surgical site infection, as well as loss of the protective effect
of prophylaxis over time (7-9). However, the actual clinical
benefit of intraoperative antibiotic redosing has not been
confirmed or quantified in either clinical trials or observa-
tional studies.
We therefore carried out a retrospective cohort study to
assess the effect of intraoperative redosing of prophylaxis on
the occurrence of surgical site infection after prolonged car-
diac procedures. Cardiac surgery was chosen for the study
because its duration is typically long enough to meet the
threshold for redosing in most published guidelines and
because it carries a substantial risk for surgical site infection
(10,11).
Methods
This retrospective cohort study involved patients oper-
ated on in the Division of Cardiac Surgery at Brigham and
Women's Hospital, Boston, Massachusetts, from April 1,
1998, to September 30, 1999. The study population was
restricted to patients who received a first preoperative 1-g
dose of cefazolin beginning <90 minutes before incision of the
skin and whose procedures lasted >240 minutes after that
dose. This minimum duration was chosen because it was the
redosing interval recommended by the hospital’s guidelines
during the study period. No antibiotic redosing was given for
any procedures of shorter duration; they would therefore not
have contributed to our study. Patients were excluded if they
received therapeutic antibiotics at the time of surgery.
Patients were included only once in the analysis.
Intraoperative redosing was defined as the administra-
tion of a second dose of cefazolin at any time before surgical
closure. In addition to the preoperative dose and an intraop-
erative redose when applicable, patients typically had at
least six additional 1-g doses of cefazolin prescribed during
the postoperative period. 
For each eligible operation, the following data were
abstracted from the anesthesiologist’s report: age and sex of
patient, date and type of surgery, surgeon, and the time of all
antibiotic administrations. In addition, data on reoperations
during the same hospital stay (except if reoperation followed
a diagnosis of a surgical site infection) were collected from
the hospital information system. To avoid comparisons
between small subgroups, surgeries were categorized as to
whether they included coronary artery bypass grafting.
Surgical site infections were prospectively identified by
modified National Nosocomial Infection Surveillance meth-
ods and criteria (1) by an infection control practitioner who
did not know whether the patient had received an intraoper-
ative redose of antibiotic. This method encompassed both
inpatient components and postdischarge information from
the surgeons’ offices. 
To compare the patients who had received intraopera-
tive redosing of cefazolin with those who had not, we used
the 2-sided Wilcoxon rank sum test for continuous variables
and the chi-square test for proportions. The significance
level was 0.05 in all tests. Significant univariate predictors
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of surgical site infection were then candidates for inclusion
in a logistic regression model that was built through a for-
ward selection process (12). The absence or presence of intra-
operative antibiotic redosing was always forced in the model,
as was an interaction term of procedure duration and intra-
operative redosing, as described below. The model was then
tested for confounding by each of the excluded covariates.
The Wald test was used to report the significance level of the
predictors in the final model (13). The odds of surgical site
infection were also compared for redosing, categorized as
either absent, given after 240 min, or given within 240 min,
with the likelihood ratio test used to assess deviance from
linearity. 
To investigate whether intraoperative redosing had dif-
ferent effects on the risk for infection across different proce-
dure durations, we created an interaction term with
duration (categorized as <300 min, 300 to 400 min, or >400
min) and intraoperative redosing. These thresholds were
chosen before the analysis began. The likelihood ratio test
was used to assess the significance of this interaction term.
Statistical analyses were performed with SAS statistical
software (SAS Inc., Cary, NC).
Results
Among 2,751 cardiac operations performed from April
1998 through September 1999, 1,886 (69%) lasted >240 min
from the time of preoperative administration of antibiotic
prophylaxis. We excluded 214 procedures (11%) because the
patients received antibiotics other than cefazolin for prophy-
laxis, 44 (2%) because cefazolin had been administered
either after surgical incision or >90 min before; 17 (1%)
because of ongoing antibiotic therapy; and 8 (0.4%) because
the patients had already been included in the analysis. Data
were available for 1,548 (97%) of the 1,603 eligible patients. 
Intraoperative redosing of cefazolin was administered to
459 (30%) of the patients, including 276 (18%) who received
it within 240 min. These patients were compared with those
who did not receive redosing (Table 1). The mean duration of
surgery, measured from the administration of the preopera-
tive dose of antibiotic, was significantly longer (p = 0.0001) in
patients who were redosed. The distribution of surgeons also
differed between the two groups. Intraoperative redosing
was not associated with any of the available covariates, i.e.,
age, sex, type of surgery, need for reoperation, or calendar
date.
Surgical site infection was diagnosed in 144 (9.3%)
patients. One third of these infections were deep. There was
no statistically significant difference among surgeon-specific
infection rates (range 7.7% to 11.3%). In the whole study
population, the overall risk for infection was similar in
patients who received intraoperative redosing of cefazolin
(43 [9.4%] of 459) and in those who did not (101 [9.3%] of
1,089) (OR 1.01, 95% CI 0.70 - 1.47). Multivariate analysis
showed that the risk for surgical site infection increased
with patient age and procedure duration and was also higher
in coronary artery bypass grafting surgery. The latter find-
ing was expected because of the additional incision for vein
graft harvesting. There was also a significant interaction
between surgery duration and intraoperative redosing (p =
0.015); redosing was associated with a lower infection rate in
the longer procedures but not shorter ones. 
Independent predictors of surgical site infection were
analyzed for two categories of procedure duration (Table 2).
Intraoperative redosing had a significant protective effect
only in procedures lasting >400 min, for which it was associ-
ated with a 0.44 odds ratio (OR; 95% confidence interval [CI]
0.23 to 0.86) of surgical site infection. This corresponds
approximately to a 56% reduction in risk for infection among
these procedures, resulting in a risk that does not differ sig-
nificantly from that observed in surgery that lasted 240 to
400 min. 
Table 1. Characteristics of patients undergoing cardiac surgery
Variable
Intraoperative antibiotic 
redosing
p
Yes
(n = 459)
No
(n = 1,089)
Mean age (range, 
years) 
65.2 (17–91) 65.7 (20–92) NSa
Mean duration of 
surgery
b
393 (241-
900)
345 (241–
700)
0.0001
Male sex (%) 328 (71.5) 744 (68.3) NS
Type of surgery
CABG 317 (69.1) 784 (72.0) NS
Others 142 (30.9) 305 (28.0)
Reoperation
c 53 (11.6) 105 (9.6) NS
aNS = not significant; CABG = coronary artery bypass graft.
bMinutes elapsed between administration of preoperative antibiotics and
skin closure.
cReoperation within the same hospital stay is included, except for surgery
following a diagnosis of surgical site infection.
Table 2. Independent predictors of surgical site infections after
cardiac surgery
Predictor
Adjusted 
odds ratio 
for SSIa
95% 
confidence 
interval pb
Procedures lasting <400 min
Age c 1.2 1.00-1.45 0.049
CABG surgery 1.84 1.05-3.20 0.032
Duration of surgeryd 1.38 1.00-1.82 0.032
Intraoperative redosing of 
antibiotics
1.27 0.80-2.02 0.319
Procedures lasting >400 min
CABG surgery 2.2 1.05-4.61 0.036
Intraoperative redosing of 
antibiotics
0.44 0.23-0.86 0.016
aSSI: surgical site infection; CABG: coronary artery bypass graft.
bWald test.
cOdds ratio for every additional decade of age.
dOdds ratio for every additional hour of surgery.Research
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We also explored different redosing schedules during
procedures of >400 min. There was a significant trend
toward a lower risk for infection when redose was either not
given, given after 240 min, or given within 240 min (p =
0.001).
Of the patients who received prophylaxis with cefazolin,
20% had a procedure that lasted >400 min. For all patients,
including those with a procedure lasting <240 min, we esti-
mate that the infection rate in the absence of any redosing
would have been 9.4%. If every patient whose procedure
lasted >240 min had been redosed, the expected infection
rate would have been 7.9%, representing a 16% reduction in
the overall risk of postoperative surgical site infection attrib-
utable to redosing. The distribution of this expected risk in
operations more or less than 400 min in duration, with or
without redosing, is shown in the Figure.
Since procedures had been arbitrarily categorized before
inspection of the data according to a duration of more or less
than 400 min, we analyzed the impact of intraoperative
redosing with different thresholds of duration. The benefit of
intraoperative redosing was significant for a boundary
between 385 and 415 min. However, there was a general
trend toward greater benefit for higher thresholds.
Discussion
This retrospective study demonstrates that intraopera-
tive redosing of cefazolin provided additional protection
against surgical site infection among patients undergoing car-
diac surgery lasting longer than approximately 6.5 to 7 h.
Although this group includes only a minority of procedures,
we estimate from our data that a strategy of redosing in all
procedures >240 min long results in a 16% reduction in the
overall infection rate in cardiac surgery. This rate in our study
population was comparable with that reported by others
(10,11,14,15). The benefit from redosing had been assumed
but had not been proven, and the minimum duration at which
redosing is beneficial had been derived from theoretical con-
siderations. Redosing provided similar protection from both
deep and superficial infections (data not shown).
The positive association between duration of surgery
and risk for surgical site infection has been reported (7-9).
Our data show that this association persists even when anti-
biotic is redosed. This observation suggests that the risk
related to duration not only reflects a diminution of antibi-
otic concentration over time but also may be a proxy for risk
factors independent of antibiotic use, such as the technical
difficulty of the procedure.
Guidelines usually recommend redosing intervals of 3 to
4 h for cefazolin (1,3-6). In a study on hysterectomy, for
instance, a protective effect of prophylaxis was no longer
observed when the operation lasted >3.3 h (8). The benefit
extended beyond this threshold in our study, a finding that
may reflect the markedly prolonged serum half-life of cefazo-
lin during cardiopulmonary bypass. Although the half-life of
cefazolin is 1.8 h in healthy persons (3), several studies have
shown a slower elimination during cardiopulmonary bypass
(14,16,17). Therefore, any benefit of redosing in noncardiac
surgery may be observed for shorter procedures than in car-
diac surgery.
This study has several limitations. Because of its retro-
spective design, the results were adjusted for a limited num-
ber of risk factors for surgical site infection, including
surgery duration, age of the patient, and need for reopera-
tion. Certain coexisting conditions, such as diabetes mellitus
or obesity, smoking status, length of previous hospital stay,
and a violation of asepsis during surgery, are among the pre-
dictors of surgical site infection that might confound our
results, should they be related to the probability of an intra-
operative antibiotic redose. Since the most plausible effect of
a high-risk profile is to increase the likelihood of intraopera-
tive redosing, adjustment for this profile would increase the
apparent benefit. If patients undergoing more complicated
(and therefore more infection-prone) procedures were less
likely to be redosed for any reason, the effect of redosing
would be overestimated. However, in that case, we would
expect to see an effect for all procedures, not only longer
ones. Our study also provides no information about the util-
ity of additional doses of prophylaxis after surgery. Finally,
our sample size limits the precision of our estimates, espe-
cially the ability to identify a precise threshold beyond which
redosing is beneficial. Thus, we do not know whether similar
protection could be obtained by redosing cefazolin only
beyond the 400-min threshold. In an exploratory analysis of
timing of the redose, there was a significant trend toward
higher benefit when a redose was given within 240 min.
Therefore, our results should not be used to support an
extension of the 3- to 4-h redosing interval recommended by
most guidelines (1,3-6).
We conclude that redosing of cefazolin prophylaxis for
most cardiac procedures can prevent a substantial fraction of
surgical site infections. It will be worthwhile to examine the
effects of intraoperative redosing in other procedures.
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Figure. Effect of intraoperative redosing of cefazolin on the probabil-
ity of surgical site infection. Box-and-whisker plots represent the
probabilities of surgical site infection in 1,548 patients undergoing
cardiac surgery, stratified by procedure duration, with or without
intraoperative redosing of cefazolin. The probabilities for each mem-
ber of the cohort were computed on the basis of redosing of antibiotic
prophylaxis, the patient’s age, and the type and duration of the pro-
cedure. The mean is represented by a triangle and the median by a
bar within the boxes. There is no bar for procedures >400 min in
duration because all the probabilities were clustered at the extremi-
ties of the boxes.Research
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